PNI to be Acquired by Danaher Corporation’s Life Sciences Platform
Currently, PNI offers a Genetic Medicine Toolkit, including its GenVoy LNP delivery platform and NanoAssemblr microfluidic-based nanoparticle manufacturing platform, for the development of genetic medicines.
Precision NanoSystems (PNI), a Canadian genetic medicines technology and solutions company, announced on June 1, 2021 that it has been acquired by Danaher Corporation’s Life Sciences platform.
Currently, PNI offers a Genetic Medicine Toolkit, including its GenVoy LNP delivery platform and NanoAssemblr microfluidic-based nanoparticle manufacturing platform, for the development of genetic medicines, the company said in a press release. PNI also plans on developing a new center of manufacturing excellence in Vancouver to enhance its therapeutic and vaccine manufacturing capabilities.
“PNI has advanced a number of exciting innovations, and we’re thrilled to welcome this talented team,” said Emmanuel Ligner, Danaher Group executive, in the press release. “As mRNA has matured as a successful technology in some COVID vaccines, we’re seeing huge potential for this technology to accelerate other therapies. The work done so far by the PNI team will also enable our customers at Cytiva and Pall [also part of Daniher] to take a huge step forward in advancing their science to improve the lives of patients.”
Source: PNI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
